Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.38 |
| ▸ | CA1 | P00915 | 7/20 | 0.38 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28613182 | 0.84 | MYC (0.32) | — | |
| SCHEMBL12992731 | 0.75 | KDM4E (0.33) | MAPT | |
| SCHEMBL4269854 | 0.75 | MEN1 (0.43) | CA2CA12CA5ACA4CA5B | |
| SCHEMBL9051200 | 0.75 | KDM4E (0.33) | MAPT | |
| SCHEMBL30631565 | 0.75 | MEN1 (0.43) | CA2CA12CA5ACA4CA5B | |
| SCHEMBL2489211 | 0.73 | CA2 (0.39) | CA2CA1CA9CA12CA6 | |
| SCHEMBL16947752 | 0.73 | PTGES2 (0.49) | CA2CA1CA9CA12CA6 | |
| SCHEMBL5032032 | 0.73 | PTGES2 (0.46) | CA2CA1CA9CA12CA6 | |
| SCHEMBL29520326 | 0.72 | CA2 (0.48) | CA2CA1CA9CA12CA6 | |
| SCHEMBL4756861 | 0.72 | CA2 (0.48) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012373-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2024-06-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012373-B2 | Cannabinoid derivatives | CNR2, CNR1, HTR2A | CA2 1853/4885CA1 4344/4885CA9 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.